Fundraising FoxZehnatx
1 known investors
Find your way into Zehnatx
Sign up to find every way you can get introduced to Zehnatx
- Your email: who you already know at Zehnatx, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Zehnatx team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Zehna Therapeutics is an early-stage biotech company developing non-bactericidal small-molecule inhibitors of gut microbial enzymes, with lead compounds targeting CutC lyase to lower TMAO levels. Its work focuses on treating cardiometabolic and chronic diseases, with chronic kidney disease as its lead indication.
Founders & leadership
CV
Camilla V. SimpsonChief Executive Officer
RM
Robert Matunas, PhDHead of CMC and Nonclinical Sciences
MB
Mike Bishop, PhDHead of Early Development and Medicinal Chemistry
Investors · 1
Related companies · 7
Sionna TherapeuticsSionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.
Serna BioSerna builds a platform to unlock the transcriptome as a drug target for drug discovery. The company integrates technology and biology to change drug discovery processes.
Syrna TherapeuticsSyrna Therapeutics is a biotech company developing small-molecule covalent translation inhibitors that bind and modify structured domains in the mRNA of disease-causing proteins to block their expression. It uses a 3D structure-guided drug discovery platform, with lead programs in immunology and neurodegeneration and a broader pipeline spanning metabolic disease and oncology.
ロゴマーク：AIRNAAIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA. The company targets diseases where the underlying genetic mechanism is well-established and difficult to address with existing therapeutic approaches.
ThernaTherna develops an AI platform that designs and optimizes programmable RNA medicines, including mRNA and antisense oligonucleotide/siRNA therapeutics, using generative AI models informed by proprietary experimental validation data.
Cleveland ClinicCleveland Clinic is a multi-specialty medical group practice and hospital system founded in 1921, providing patient care, medical research, and education. It operates facilities in the United States and internationally, with its base in Northeast Ohio.
DoximityDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
Companies working in the same space as Zehnatx.
Frequently asked questions
- What does Zehnatx do?
- Zehna Therapeutics is an early-stage biotech company developing non-bactericidal small-molecule inhibitors of gut microbial enzymes, with lead compounds targeting CutC lyase to lower TMAO levels. Its work focuses on treating cardiometabolic and chronic diseases, with chronic kidney disease as its lead indication.
- Who are Zehnatx's investors?
- Zehnatx's investors include JobsOhio Ventures.